These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 20874249)
1. Current and future role of interferon beta in the therapy of multiple sclerosis. Farrell RA; Giovannoni G J Interferon Cytokine Res; 2010 Oct; 30(10):715-26. PubMed ID: 20874249 [TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Pula JH; Javed A Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach? Chofflon M BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071 [TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM; Johnson BH; Wenten M; Watson C Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422 [TBL] [Abstract][Full Text] [Related]
19. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Berger JR Am J Manag Care; 2011 May; 17 Suppl 5 Improving():S146-53. PubMed ID: 21761953 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]